A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.
A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.
The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin
 analogues will improve post prandial glycaemic control in patients with type 1 diabetes.

 OBJECTIVE:

 The objective is to describe pharmacodynamic (PD) and pharmacokinetic (PK) profiles of
 Insulin Aspart (IAsp), Biphasic Insulin Aspart (BIAsp) 30, 50 and 70 for a period of 12 hours
 following a standard test meal on four days respectively in subjects with type 1 diabetes.
This trial is a single centre, open-label, randomised 4 period cross-over trial, comparing
 the pk and pd profiles of IAsp, BIAsp 30, BIAsp 50 and BIAsp 70 after a standard test meal in
 subjects with type 1 diabetes. The profiles will be derived over a 12-hour period after
 subcutaneous injection in the abdominal region with a single dose of IAsp, BIAsp 30, BIAsp 50
 or BIAsp 70 at a test meal. The trial consists of a screening period of 4-21 days and 4
 treatment visits
Inclusion Criteria:

 1. Informed consent obtained before any trial-related activities.

 2. Diagnosed type 1 diabetes before the age of 40 and on insulin treatment within one
 year of diagnosis.

 3. Insulin treatment of any regime for more than one year at time of inclusion.

 4. Total insulin demand ≥ 0,5 IU/kg/24 hrs

 5. HbA1c between 7% and 12 % (both values included).

 6. Age ≥ 18 years.

 7. BMI between 18 and 35 kg /m2 (including both values).

 Exclusion Criteria:

 1. Known or suspected allergy to trial product(s) or related products.

 2. Recurrent major hypoglycaemic episodes.

 3. Heart: Unstable Angina Pectoris, AMI < 12 months or heart insufficiency classified
 according to NYHA III-IV

 4. Blood Pressure: Severe uncontrolled hypertension with BP > 180/110 mmHg, sitting

 5. Liver: Impaired hepatic function corresponding to serum-ALAT or -basic phosphatase >
 2x upper reference limit of the local laboratory.

 6. Kidneys: Impaired renal function corresponding to serum-creatinin > 150 μmol/l
 according to the local laboratory.

 7. Any disease judged by the investigator to affect the trial.

 8. Pregnancy, breast feeding or the intention of becoming pregnant or fertile women not
 using adequate contraceptive measures - adequate contraceptive method is
 sterilisation, hysterectomy or current use of contraceptive pills or intra uterine
 device.

 9. The receipt of any investigational drug within a three month period prior to this
 trial.